CMS Ties Hyaluronidase SC Drugs to Originals
New Medicare negotiation rules group certain subcutaneous combination formulations with their original drugs, and Alteogen shares fell sharply in Seoul.
Updated on Nov. 9, 2026 in Healthcare

The U.S. Centers for Medicare & Medicaid Services finalized drug price negotiation regulations on November 6, 2026, grouping certain hyaluronidase-based subcutaneous combination formulations with their original drugs for negotiation eligibility. Alteogen, which holds the Hybrozyme platform, fell 15.71% on KOSDAQ on November 9.
Why it matters
Pharmaceutical companies had treated hyaluronidase-based subcutaneous formulations as separate combination drugs for negotiation purposes, a approach that could have delayed price negotiation. The rule change may limit that strategy, which the market appears to be weighing.
Alteogen traded at 169,000 Korean won at 9:43 AM on November 9, 2026, down 31,500 won or 15.71% from the previous session. The number of drugs affected by the grouping rule and its projected revenue impact were not disclosed in the source material.
The players
Centers for Medicare & Medicaid Services (CMS)
The federal agency that administers Medicare and Medicaid and issued the final drug price negotiation regulations.
Alteogen
A South Korean biopharmaceutical company whose Hybrozyme platform converts intravenous biologics into subcutaneous formulations.
The details
The regulations address hyaluronidase-based formulations, which reformulate intravenous biologics for subcutaneous delivery and reduce administration time. Under the new rule, such combinations are grouped with the original drug for price negotiation purposes rather than assessed separately.
Timeline
November 6, 2026: CMS announced the final drug price negotiation regulations.
November 9, 2026: Alteogen shares fell 15.71% on KOSDAQ during morning trading.
Market Landscape
The rule applies the Medicare drug price negotiation framework to hyaluronidase-based subcutaneous combinations, a formulation approach that had been used to position drugs differently for negotiation timing. Alteogen's sharp share decline reflects investor attention to whether such conversion strategies will keep their expected value under the final rules.
Patients receiving subcutaneous versions of biologic drugs may see those products handled under the same negotiation timeline as their original drugs. Pricing outcomes for individual medications will depend on how the negotiation process applies to each affected product.
The takeaway
Pharmaceutical strategies that rely on reformulation to shift regulatory timelines are subject to change as federal rules are finalized. Readers tracking drug costs should watch how CMS applies these groupings in practice.
Further reading
Explore more coverage in Healthcare for context on federal drug pricing policy.






